Company achieves major milestones in clinical development programs in 2022 Patient treatment in Acclaim-2 clinical trial commences
Company Has FDA Fast Track Designation for Combination of REQORSA and Keytruda
Company has FDA Fast Track Designation for combination of REQORSA and Tagrisso
Multiple clinical trial sites to be opened under oncology research network collaboration
Genprex announced that the FDA has confirmed all comments have been addressed regarding the Company’s protocol for the Acclaim-1 clinical trial
Company achieves another milestone relating to its clinical trial strategy
Acclaim-2 Clinical Trial Combines REQORSA™ immunogene therapy with Merck & Co’s Keytruda®
Collaborators presented positive preclinical data for the combination of TUSC2 immunogene therapy (REQORSA™) in combination with chemotherapy and immunotherapies for the treatment of non-small cell lung cancer (NSCLC).
Major Manufacturing Milestone Positions the Company for Success In the Lung Cancer Therapeutics Market, Expected to Grow to $26.3 Billion by 2023
Designed and Secured by Barsec